10.6084/M9.FIGSHARE.C.6292383.V1
Yin Liu
Yin
Liu
Soochow University
First Affiliated Hospital of Soochow University
Ye Zhao
Ye
Zhao
Soochow University
First Affiliated Hospital of Soochow University
Jiaqian Qi
Jiaqian
Qi
Soochow University
First Affiliated Hospital of Soochow University
Xiao Ma
Xiao
Ma
First Affiliated Hospital of Soochow University
Xiaofei Qi
Xiaofei
Qi
First Affiliated Hospital of Soochow University
Depei Wu
Depei
Wu
Soochow University
First Affiliated Hospital of Soochow University
Yang Xu
Yang
Xu
Soochow University
First Affiliated Hospital of Soochow University
Fecal microbiota transplantation combined with ruxolitinib as a salvage treatment for intestinal steroid-refractory acute GVHD
Abstract Acute graft-versus-host disease (aGVHD), especially intestinal aGVHD, is one of the most severe complications after allogeneic hematopoietic stem cell transplantation (HSCT). Fecal microbiota transplantation (FMT) has been applied to the treatment of intestinal steroid-refractory aGVHD (SR-aGVHD). Ruxolitinib is the first drug recommended for SR-aGVHD. Here, we reported the outcome data from 21 patients who had received the combined treatment of FMT with ruxolitinib as a salvage treatment in intestinal SR-aGVHD after HSCT. The overall response rate on day 28 was 71.4% (95% CI 50.4–92.5%), including 10 patients with complete responses. The durable overall response at day 56 in responders was 80%. GVHD relapse rate was 33.3% in responders. The levels of inflammatory cytokines as well as T cells and NK cells activation declined. The diversity of the intestinal microbiota was improved in responders. Viral reactivations and severe cytopenia were the major adverse events (61.9% and 81% respectively). The estimated 6-month overall survival was 57.1% (95% CI: 35.9–78.3%), while event-free survival was 52.4% (95% CI: 21.7%-64.1%). Collectively, FMT with ruxolitinib could be an effective treatment for intestinal SR-aGVHD after HSCT. Trial registration: ClinicalTrials.gov identifier: NCT03148743.
Medicine
Microbiology
Physiology
Pharmacology
Biotechnology
Chemical Sciences not elsewhere classified
Ecology
Immunology
Developmental Biology
Cancer
Science Policy
Infectious Diseases
figshare
2022
2022-11-10
2022-11-10
Collection
10.6084/m9.figshare.c.6292383
CC BY 4.0